Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Robert Fogel

Showing results (11-20 of 40) with videos related to

Pageof 4
Sort By:
Chest|May 20, 2019
Differences in COPD Exacerbation Risk Between Women and Men: Analysis From the UK Clinical Practice Research Datalink DataDaiana Stolz, Konstantinos Kostikas, Emil Loefroth, et al.
International Journal of Chronic Obstructive Pulmonary Disease|February 9, 2017
Indacaterol/glycopyrronium versus salmeterol/fluticasone in Asian patients with COPD at a high risk of exacerbations: results from the FLAME studyJadwiga A Wedzicha, Nanshan Zhong, Masakazu Ichinose, et al.
International Journal of Chronic Obstructive Pulmonary Disease|December 24, 2016
Indacaterol/glycopyrronium in symptomatic patients with COPD (GOLD B and GOLD D) versus salmeterol/fluticasone: ILLUMINATE/LANTERN pooled analysisClaus Vogelmeier, Nanshan Zhong, Michael J Humphries, et al.
Academic Radiology|September 16, 2008
Hyperpolarized 3He magnetic resonance imaging of chronic obstructive pulmonary disease: reproducibility at 3.0 teslaLindsay Mathew, Andrea Evans, Alexei Ouriadov, et al.
Respiratory Medicine|August 20, 2014
Pooled safety analysis of the fixed-dose combination of indacaterol and glycopyrronium (QVA149), its monocomponents, and tiotropium versus placebo in COPD patientsJadwiga A Wedzicha, Ronald Dahl, Roland Buhl, et al.
Sleep|November 10, 2004
Postural effects on pharyngeal protective reflex mechanismsAtul Malhotra, John Trinder, Robert Fogel, et al.
International Journal of Chronic Obstructive Pulmonary Disease|August 9, 2020
Clinical Impact and Healthcare Resource Utilization Associated with Early versus Late COPD Diagnosis in Patients from UK CPRD DatabaseKonstantinos Kostikas, David Price, Florian S Gutzwiller, et al.
International Journal of Chronic Obstructive Pulmonary Disease|April 1, 2017
LABA/LAMA combinations versus LAMA monotherapy or LABA/ICS in COPD: a systematic review and meta-analysisGustavo J Rodrigo, David Price, Antonio Anzueto, et al.
Nature Reviews. Drug Discovery|May 23, 2015
Drug development for airway diseases: looking forwardStephen Holgate, Alvar Agusti, Robert M Strieter, et al.
International Journal of Chronic Obstructive Pulmonary Disease|May 13, 2017
The effect of indacaterol/glycopyrronium versus tiotropium or salmeterol/fluticasone on the prevention of clinically important deterioration in COPDAntonio R Anzueto, Claus F Vogelmeier, Konstantinos Kostikas, et al.
Pageof 4

Showing results (11-20 of 40) with videos related to

Sort By:
Pageof 4
Chest|May 20, 2019
Differences in COPD Exacerbation Risk Between Women and Men: Analysis From the UK Clinical Practice Research Datalink DataDaiana Stolz, Konstantinos Kostikas, Emil Loefroth, et al.
International Journal of Chronic Obstructive Pulmonary Disease|February 9, 2017
Indacaterol/glycopyrronium versus salmeterol/fluticasone in Asian patients with COPD at a high risk of exacerbations: results from the FLAME studyJadwiga A Wedzicha, Nanshan Zhong, Masakazu Ichinose, et al.
International Journal of Chronic Obstructive Pulmonary Disease|December 24, 2016
Indacaterol/glycopyrronium in symptomatic patients with COPD (GOLD B and GOLD D) versus salmeterol/fluticasone: ILLUMINATE/LANTERN pooled analysisClaus Vogelmeier, Nanshan Zhong, Michael J Humphries, et al.
Academic Radiology|September 16, 2008
Hyperpolarized 3He magnetic resonance imaging of chronic obstructive pulmonary disease: reproducibility at 3.0 teslaLindsay Mathew, Andrea Evans, Alexei Ouriadov, et al.
Respiratory Medicine|August 20, 2014
Pooled safety analysis of the fixed-dose combination of indacaterol and glycopyrronium (QVA149), its monocomponents, and tiotropium versus placebo in COPD patientsJadwiga A Wedzicha, Ronald Dahl, Roland Buhl, et al.
Sleep|November 10, 2004
Postural effects on pharyngeal protective reflex mechanismsAtul Malhotra, John Trinder, Robert Fogel, et al.
International Journal of Chronic Obstructive Pulmonary Disease|August 9, 2020
Clinical Impact and Healthcare Resource Utilization Associated with Early versus Late COPD Diagnosis in Patients from UK CPRD DatabaseKonstantinos Kostikas, David Price, Florian S Gutzwiller, et al.
International Journal of Chronic Obstructive Pulmonary Disease|April 1, 2017
LABA/LAMA combinations versus LAMA monotherapy or LABA/ICS in COPD: a systematic review and meta-analysisGustavo J Rodrigo, David Price, Antonio Anzueto, et al.
Nature Reviews. Drug Discovery|May 23, 2015
Drug development for airway diseases: looking forwardStephen Holgate, Alvar Agusti, Robert M Strieter, et al.
International Journal of Chronic Obstructive Pulmonary Disease|May 13, 2017
The effect of indacaterol/glycopyrronium versus tiotropium or salmeterol/fluticasone on the prevention of clinically important deterioration in COPDAntonio R Anzueto, Claus F Vogelmeier, Konstantinos Kostikas, et al.
Pageof 4